# Shanghai JMT-Bio Inc. clinical trials: 42 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with Shanghai JMT-Bio Inc. as lead sponsor, 27 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shanghai JMT-Bio Inc.: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-jmt-bio-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2026 | NCT07840729 | Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants | Shanghai JMT-Bio Inc. | Phase 1 | Recruiting | Valid MeSH Conditiongs | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840729) |
| April 22, 2026 | NCT07545044 | A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or... | Shanghai JMT-Bio Inc. | Phase 2 | Not yet recruiting | HER2-positive Recurrent or Metastatic Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545044) |
| March 16, 2026 | NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | Shanghai JMT-Bio Inc. | Phase 1/2 | Not yet recruiting | Non-Small Cell Lung Cancer, Small Cell Lung Cancer | 596 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472647) |
| March 2, 2026 | NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | Shanghai JMT-Bio Inc. | Phase 3 | Recruiting | Resectable HER2-positive Breast Cancer | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441460) |
| February 19, 2026 | NCT07419698 | Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants | Shanghai JMT-Bio Inc. | Phase 1 | Recruiting | Healthy Participants | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419698) |
| February 3, 2026 | NCT07384377 | JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to... | Shanghai JMT-Bio Inc. | Phase 3 | Not yet recruiting | HER2-positive Colorectal Cancer | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07384377) |
| January 12, 2026 | NCT07332533 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | Shanghai JMT-Bio Inc. | Phase 2/3 | Not yet recruiting | HER2-positive Gastric Cancer | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332533) |
| December 12, 2025 | NCT07280832 | Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors | Shanghai JMT-Bio Inc. | Phase 1/2 | Recruiting | Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07280832) |
| December 10, 2025 | NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | Shanghai JMT-Bio Inc. | Phase 1 | Recruiting | Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07275073) |
| August 26, 2025 | NCT07140809 | a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia | Shanghai JMT-Bio Inc. | Phase 1/2 | Recruiting | Hypertriglyceridemia | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07140809) |
| August 21, 2025 | NCT07134205 | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | Shanghai JMT-Bio Inc. | Phase 3 | Not yet recruiting | Metastatic Colorectal Cancer (mCRC) | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07134205) |
| June 19, 2025 | NCT07029139 | A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy | Shanghai JMT-Bio Inc. | Phase 2 | Not yet recruiting | Primary Membranous Nephropathy | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029139) |
| May 31, 2025 | NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | Shanghai JMT-Bio Inc. | Phase 2 | Not yet recruiting | HER2-positive Gastric Cancer | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06998771) |
| April 3, 2025 | NCT06908772 | Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients | Shanghai JMT-Bio Inc. | Phase 2/3 | Not yet recruiting | Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06908772) |
| March 24, 2025 | NCT06892431 | JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer | Shanghai JMT-Bio Inc. | Phase 2 | Not yet recruiting | Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892431) |
| March 14, 2025 | NCT06877650 | First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors | Shanghai JMT-Bio Inc. | Phase 1/2 | Recruiting | Advanced Malignant Tumors | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06877650) |
| March 11, 2025 | NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | Shanghai JMT-Bio Inc. | Phase 1/2 | Recruiting | Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia, Pancreatic Cancer Cachexia | 307 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06868849) |
| February 26, 2025 | NCT06846437 | JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer | Shanghai JMT-Bio Inc. | Phase 3 | Recruiting | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06846437) |
| February 17, 2025 | NCT06829459 | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in... | Shanghai JMT-Bio Inc. | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06829459) |
| December 24, 2024 | NCT06747338 | A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive... | Shanghai JMT-Bio Inc. | Phase 3 | Active not recruiting | Early or Locally Advanced HER2-positive Breast Cancer | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06747338) |
| December 16, 2024 | NCT06735391 | A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally... | Shanghai JMT-Bio Inc. | Phase 3 | Recruiting | Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated... | 516 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06735391) |
| December 10, 2024 | NCT06725524 | A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma | Shanghai JMT-Bio Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06725524) |
| August 21, 2024 | NCT06564467 | A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202 | Shanghai JMT-Bio Inc. | Phase 1 | Unknown | Healthy Subjects | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06564467) |
| April 30, 2024 | NCT06391944 | JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor... | Shanghai JMT-Bio Inc. | Phase 2 | Active not recruiting | Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06391944) |
| April 23, 2024 | NCT06380348 | JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung... | Shanghai JMT-Bio Inc. | Phase 3 | Not yet recruiting | Local Advanced or Metastatic NSCLC | 398 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06380348) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 7 |
| Phase 2 | 9 |
| Phase 2/3 | 4 |
| Phase 3 | 11 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 14 |
| Not yet recruiting | 13 |
| Unknown | 10 |
| Completed | 2 |
| Active not recruiting | 2 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Giant Cell Tumor of Bone | 3 |
| Recurrence | 2 |
| Colorectal Neoplasms | 2 |
| Breast Neoplasms | 2 |
| Pancreatic Neoplasms | 1 |
| Nasopharyngeal Neoplasms | 1 |
| Hypertriglyceridemia | 1 |
| Melanoma | 1 |
| Humoral Hypercalcemia Of Malignancy | 1 |
| Small Cell Lung Carcinoma | 1 |
| Stomach Neoplasms | 1 |
| Osteoporosis, Postmenopausal | 1 |
| Carcinoma, Hepatocellular | 1 |
| Lymphoma, B-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Workers compensation law firms in the United States](https://specstream.ai/data/businesses/workers-compensation-law-firms/united-states)
- [German restaurants in the United States](https://specstream.ai/data/businesses/german-restaurants/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
- [Persian restaurants in the United States](https://specstream.ai/data/businesses/persian-restaurants/united-states)
- [Beer bars in the United States](https://specstream.ai/data/businesses/beer-bars/united-states)
